Latest news with #SFATherapeutics
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034) Due to Demand for Targeted Autoimmune Therapies
The interleukin-23 inhibitors market is witnessing robust growth driven by the rising prevalence of autoimmune diseases like psoriasis and inflammatory bowel disease. Advancements in biologics and increased adoption of targeted therapies are further accelerating demand. Favorable reimbursement policies and growing awareness among healthcare providers are also contributing to market expansion. The IL-23 inhibitors market is expected to maintain strong momentum with ongoing R&D and label expansions. LAS VEGAS, Aug. 14, 2025 /PRNewswire/ — DelveInsight's Interleukin-23 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging interleukin-23 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Interleukin-23 Inhibitors Market Report As per DelveInsight's analysis, the total market size of interleukin-23 inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others. Leading interleukin-23 inhibitor companies, such as Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, SFA Therapeutics, BioVie, and others, are developing novel Interleukin-23 inhibitors that can be available in the interleukin-23 inhibitors market in the coming years. Some of the key interleukin-23 inhibitors in the pipeline include Icotrokinra (JNJ-77242113), SFA-002, Bezisterim (NE3107), and others. In April 2025, Johnson & Johnson released new Icotrokinra data from a subgroup analysis of ICONIC-LEAD in moderate-to-severe plaque psoriasis to assess the efficacy and safety of systemic therapy in adolescents and adults simultaneously. These data were presented at the 2025 WCPD annual meeting. In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida. In March 2025, SFA Therapeutics announced positive data from its Phase Ib clinical trial of SFA-002, an oral treatment for mild-to-moderate chronic plaque psoriasis. The study met its primary endpoint of safety, with no TRAEs or toxicities observed during the treatment period, and no rebound effects were noted. In March 2025, Sun Pharmaceuticals announced presentation of a Phase IIIb, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of ILUMYA for the treatment of moderate-to-severe psoriasis affecting the nails, results, at the 2025 American Academy of Dermatology (AAD) conference. In February 2025, Johnson & Johnson announced the submission of TREMFYA for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis to the European Medicines Agency (EMA). Discover which indication is expected to grab the major interleukin-23 inhibitors market share @ Interleukin-23 Inhibitors Market Report Interleukin-23 Inhibitors Market Dynamics The interleukin-23 inhibitors market has seen significant growth in recent years, driven primarily by the increasing global burden of autoimmune diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Targeted therapies that inhibit the IL-23 pathway, particularly those that block the p19 subunit, have demonstrated superior efficacy and safety profiles compared to older biologics, thus gaining rapid adoption among healthcare providers and patients. A key driver of this market is the successful commercialization of biologics such as SKYRIZI, TREMFYA, ILUMYA/ILUMETRI, and the more recent OMVOH, which specifically target the IL-23 p19 subunit. These agents offer improved disease control, convenient dosing schedules, and lower immunogenicity, which enhances long-term adherence. Additionally, their favorable safety profiles relative to older tumor necrosis factor (TNF) inhibitors have made them attractive options, particularly for patients who fail to respond to first-line treatments. Continued clinical success, coupled with positive real-world outcomes data, has further solidified their position in treatment algorithms. Despite the growth potential, the IL-23 inhibitors market also faces certain restraints and challenges. The high cost of biologic therapies can limit patient access, particularly in low- and middle-income countries where reimbursement and insurance coverage are limited. Biosimilar development remains a potential future threat, although the structural complexity of monoclonal antibodies like IL-23 inhibitors presents higher barriers to entry for biosimilar manufacturers compared to small molecules. Additionally, competition from other targeted pathways such as IL-17, IL-12/23 dual inhibitors, and emerging oral small molecules (e.g., JAK inhibitors and TYK2 inhibitors) may impact market share over time. On the innovation front, ongoing clinical research is expanding the potential of IL-23 inhibitors beyond dermatology and gastroenterology. Several studies are investigating their utility in axial spondyloarthritis, hidradenitis suppurativa, and even systemic lupus erythematosus. Moreover, pharmaceutical companies are exploring combination therapies and long-acting formulations to differentiate their products and enhance patient outcomes. These efforts are likely to diversify the application landscape and reinforce market momentum. In summary, the IL-23 inhibitors market is poised for sustained growth, underpinned by robust clinical efficacy, expanding indications, and continued physician and patient preference for targeted biologics. However, manufacturers must navigate cost-related barriers, evolving competition, and regulatory complexities to maintain their competitive edge in this dynamic therapeutic space. Interleukin-23 Inhibitors Treatment Market Currently, multiple IL-23 inhibitors are available in the market, with recent introductions including OMVOH (mirikizumab-mrkz), SKYRIZI (risankizumab-rzaa), ILUMYA/ILUMETRI (tildrakizumab-asmn), TREMFYA (guselkumab), and others. SKYRIZI is an IL-23 inhibitor that specifically targets the p19 subunit of the IL-23 cytokine. It is a biologic therapy approved for use in North America, the EU, and Japan for the treatment of psoriatic conditions such as psoriasis and psoriatic arthritis. The drug is administered via subcutaneous injection every three months, following two initial loading doses. SKYRIZI is a humanized IgG1 monoclonal antibody that binds selectively to the p19 subunit, blocking IL-23's interaction with its receptor and thereby suppressing the release of pro-inflammatory cytokines and chemokines. In April 2019, the US FDA approved SKYRIZI for treating moderate-to-severe plaque psoriasis. The same year, the European Commission also approved its use for adult patients eligible for systemic therapy. In March 2019, AbbVie announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved SKYRIZI for treating plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis in adults with inadequate response to standard therapies. ILUMYA, another IL-23 inhibitor, is a humanized IgG1/k monoclonal antibody that also selectively binds to the p19 subunit of IL-23, blocking its receptor interaction and reducing the release of pro-inflammatory mediators. In May 2018, the US FDA approved ILUMYA for adults with moderate-to-severe plaque psoriasis who are suitable candidates for systemic treatment or phototherapy. Later, in September 2018, Sun Pharmaceuticals announced that its European partner, Almirall, received European Commission approval to market ILUMETRI for adults with moderate-to-severe chronic plaque psoriasis. In September 2020, Sun Pharma also launched ILUMYA in Japan for adults with plaque psoriasis unresponsive to conventional therapies. Learn more about the interleukin-23 inhibitors @ Interleukin-23 Inhibitors Analysis Key Emerging Interleukin-23 Inhibitors and Companies IL-23 inhibitors have a pipeline consisting of products such as icotrokinra (JNJ-77242113), SFA-002, bezisterim (NE3107), and others, which are in late Phases (III and II). Icotrokinra is the first oral peptide specifically engineered to target and inhibit the IL-23 receptor, a key driver of inflammation in moderate-to-severe plaque psoriasis. It also shows promise in treating other diseases mediated by IL-23. The compound binds to the IL-23 receptor with exceptionally high affinity (in the single-digit picomolar range) and effectively suppresses IL-23 signaling in human T cells with high selectivity. The molecule emerged from a 2017 licensing and collaboration agreement between Protagonist Therapeutics and Johnson & Johnson, which aimed to discover and develop next-generation therapeutics. In May 2024, Johnson & Johnson shared new findings from the Phase III ICONIC-TOTALa trial evaluating icotrokinra in adults and adolescents (aged 12 and above) with as little as 1% body surface area involvement and at least moderate plaque psoriasis affecting sensitive, high-impact areas. According to the company's Q1 2025 earnings presentation, additional Phase III data from the ICONIC-LEAD, ICONIC-ADVANCE 1/2, and ICONIC-TOTAL studies are expected later in 2025. SFA-002 is a novel, first-in-class oral immunomodulator designed to treat autoimmune diseases, beginning with mild-to-moderate chronic plaque psoriasis. Unlike current treatments that suppress a single inflammatory pathway, SFA-002 simultaneously downregulates several key proinflammatory cytokines, TNF-α, IL-23, IL-10, IL-12, IL-17, and IFN-γ, while modulating the immune response. This multi-pathway mechanism provides a broader therapeutic effect without the immunosuppressive risks of injectable therapies. Currently in Phase Ib clinical trials, SFA-002 has shown strong efficacy with an excellent safety profile and no reported adverse events, positioning it as a potential game-changer in the treatment of autoimmune conditions. The anticipated launch of these emerging therapies are poised to transform the interleukin-23 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the interleukin-23 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about interleukin-23 inhibitors clinical trials, visit @ Interleukin-23 Inhibitors Treatment Interleukin-23 Inhibitors Overview Interleukin-23 (IL-23) inhibitors are monoclonal antibodies that specifically target the p19 subunit of IL-23, a key cytokine responsible for the activation and persistence of Th17 cells. By blocking IL-23 signaling, these agents reduce the production of pro-inflammatory cytokines like IL-17A, IL-17F, and IL-22, thereby controlling inflammation and slowing the progression of immune-mediated disorders. These inhibitors are approved for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, particularly in patients who have not responded adequately to traditional systemic therapies or TNF-α inhibitors. Their therapeutic effect is primarily achieved through disruption of the IL-23/Th17 pathway, a critical driver of chronic inflammation in these conditions. Inhibiting IL-23 results in reduced Th17 cell activity and cytokine release, leading to marked clinical improvement. Interleukin-23 Inhibitors Epidemiology Segmentation The interleukin-23 inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for IL-23 Inhibitor Total Eligible Patient Pool of Selected Indications for IL-23 Inhibitor Total Treated Cases of Selected Indications for IL-23 Inhibitor Interleukin-23 Inhibitors Report Metrics Details Study Period 2020–2034 Interleukin-23 Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others Key Interleukin-23 Inhibitors Companies Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, SFA Therapeutics, BioVie, Eli Lilly, AbbVie, Boehringer Ingelheim, Sun Pharmaceutical, Almirall, and others Key Interleukin-23 Inhibitors Icotrokinra (JNJ-77242113), SFA-002, Bezisterim (NE3107), OMVOH, SKYRIZI, ILUMYA/ILUMETRI, TREMFYA, and others Scope of the Interleukin-23 Inhibitors Market Report Interleukin-23 Inhibitors Therapeutic Assessment: Interleukin-23 Inhibitors current marketed and emerging therapies Interleukin-23 Inhibitors Market Dynamics: Conjoint Analysis of Emerging Interleukin-23 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Interleukin-23 Inhibitors Market Access and Reimbursement Discover more about interleukin-23 inhibitors in development @ Interleukin-23 Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of Interleukin-23 (IL-23) Inhibitors 4 Key Events 5 Epidemiology and Market Forecast Methodology of IL-23 Inhibitor 6 IL-23 Inhibitor Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2025 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2025 6.4 Market Share (%) Distribution by Indications in 2034 7 IL-23 Inhibitor: Background and Overview 7.1 Introduction 7.2 Potential of IL-23 Inhibitor in Different Indications 7.3 Clinical Applications of IL-23 Inhibitor 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases of Selected Indications for IL-23 Inhibitor in the 7MM 8.5 Total Eligible Patient Pool of IL-23 Inhibitor in Selected Indications in the 7MM 8.6 Total Treated Cases of Selected Indications for IL-23 Inhibitor in the 7MM 9 Marketed Products of IL-23 Inhibitor 9.1 Key Competitors 9.2 SKYRIZI (risankizumab-rzaa): AbbVie/Boehringer Ingelheim 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development 9.2.4.1 Clinical Trial Information 9.2.5 Safety and Efficacy 9.2.6 Analyst Views 9.3 ILUMYA/ILUMETRI (tildrakizumab-asmn): Sun Pharma List to be continued in the final report… 10 Emerging Therapies of IL-23 Inhibitor 10.1 Key Competitors 10.2 Icotrokinra (JNJ-77242113): Johnson & Johnson/ Innovative Medicine/Protagonist Therapeutics 10.2.1 Product Description 10.2.2 Other Developmental Activities 10.2.3 Clinical Development 10.2.3.1 Clinical Trial Information 10.2.4 Safety and Efficacy 10.2.5 Analyst Views 10.3 SFA-002: SFA Therapeutics List to be continued in the final report… 11 IL-23 Inhibitor: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook of IL-23 Inhibitor 11.3 Conjoint Analysis of IL-23 Inhibitor 11.4 Key Market Forecast Assumptions of IL-23 Inhibitor 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of IL-23 Inhibitor in the 7MM 11.6 Market Size of IL-23 Inhibitor by Indication in the7MM 11.7 The United States Market Size 11.7.1 Total Market Size of IL-23 Inhibitors in the US 11.7.2 Market Size of IL-23 Inhibitor by Indication in the US 11.7.3 Market Size of IL-23 Inhibitor by Therapies in the US 11.8 EU4 and the UK Market Size 11.9 Japan Market Size 12 Market Access and Reimbursement of IL-23 Inhibitors 13 SWOT Analysis of IL-23 Inhibitors 14 KOL Views of IL-23 Inhibitors 15 Unmet Needs of IL-23 Inhibitors 16 Bibliography 17 Report Methodology Related Reports Interleukin-2 Inhibitors Market Interleukin-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-2 inhibitors companies, including Mural Oncology, Corvus Pharmaceuticals, Philogen, Merck, Nektar, Cue Biopharma, Krystal Biotech, ILTOO Pharma, Innovent, Regeneron Pharmaceuticals, R2T Biopharma (XEME Biopharma), AstraZeneca, GI Innovation, Merck, R2T Biopharma (XEME Biopharma), Sanofi, Synthekine, BioNTech, Medicenna Therapeutics, Ascendis Pharma, Sanofi, Synthorx, Cugene, AbbVie, Deka Biosciences, Dragonfly Therapeutics, Werewolf Therapeutics, Xilio Therapeutics, Bioniz Therapeutics, Equillium, Asher Bio, Synthekine, Anaveon, Aulos Bioscience, Selecxine, ProBio, Hoffmann-La Roche, TILT Biotherapeutics, among others. Crohn's Disease Market Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including RedHill Biopharma, Arena Pharmaceuticals, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, Morphic Therapeutics, NImmune, Avobis Bio, Alimentiv, Abivax S.A., Roche, Mesoblast, Takeda, AstraZeneca, among others. Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others. Psoriasis Market Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Technical.ly
25-06-2025
- Business
- Technical.ly
Inside Philadelphia's startup surge: 16 ventures to watch right now
After years of developing a vibrant entrepreneurial ecosystem, Philadelphia is getting some recognition as a top startup community. A recent report from Startup Genome and the Global Entrepreneurship Network ranked Philly as the 13th best place in the world to start a company. The report called out the region's focus on life sciences, AI, big data, robotics and advanced manufacturing. Longtime ecosystem supporters like Ben Franklin Technology Partners know there's no shortage of promising new companies emerging from the Philadelphia scene, and they deserve attention for both the innovative solutions they're creating and the value they're adding to the local community. Explore the roundup below for a sampling of these notable startups, and check out the full articles to learn more about the companies and their stories. CollX CollX's app uses AI to scan, identify and price trading cards. The platform also has a marketplace, where users can buy and sell cards. CollX launched in 2021 as a tool to help trading card collectors understand the value of their cards. The platform has a visual search function that scrapes pricing data from other websites to estimate how much cards are worth. AmorSui, a sustainable personal protective equipment (PPE) company founded in Philadelphia by Beau Wangtrakuldee in 2018, was created to solve several problems with PPE, not least of which is the fact that it often doesn't fit all body types or protect from lab accidents. Finding a better lab coat — one that was designed for a smaller-framed woman rather than an average-sized man, made of material that protected the skin — turned out to be a fruitless endeavor. By 2015, when Wangtrakuldee was doing her postdoctoral fellowship at the University of Pennsylvania, she realized while taking a course on entrepreneurship that the business potential for higher quality, better-fitting lab coats was there. DrayNow Conshohocken-based DrayNow uses tech to move shipping containers on the first and last mile of their shipping journeys with a namesake app that Michael Dugas, director of business enablement for DrayNow describes as 'Uber for truck drivers.' Independent container truck drivers with their own vehicles use the DrayNow app to find jobs transporting freight. SFA Therapeutics The venture-backed SFA Therapeutics is developing multiple autoimmune disease-treating drugs, all based on a platform technology called SFA that was discovered by Mark Feitelson of Temple University, the startup's chief scientific officer. Keriton In 2016, Laura Carpenter, a lactation consultant with the Hospital at the University of Pennsylvania, set out to find a better way to manage breast milk feeding in the NICU. She wasn't a technologist herself, so she brought the challenge to Penn Engineering's PennApps hackathon, with support from the Penn Center for Innovation. The topic struck a chord with Vidur Bhatnagar, a hackathon participant who had personal experience with the NICU from the patient side. Bhatnagar would become the founder of Keriton, a NICU feeding technology app now used in dozens of hospitals across the country. Bainbridge Health The Children's Hospital of Philadelphia (CHOP) spinout Bainbridge Health has been collecting and analyzing medical data since 2016. It has a goal of streamlining the hospital data aggregation and analysis process to give clinicians the information they need to make their work both safer for the patients and more efficient, with less wasted medicine. Strados Labs Strados developed the RESP Biosensor, an FDA 510(k)-cleared wearable device that allows researchers and clinicians to remotely capture lung sounds between in-person clinical visits. The product is a wearable device that adheres to the chest. In real time, it records lung sound data and securely transfers it to a mobile app and the Strados cloud, where the sound data can be remotely identified by machine learning algorithms. The reports it generates show every cough, wheeze and crackle of the lungs, with timestamps. American Treatment Network American Treatment Network CEO Matthew Sullivan founded the Havertown, Pennsylvania-based company in 2018 to address the opioid and mental health crises by emphasizing treatment that integrates treating both addiction and mental illness by prioritizing the inpatient care that may follow an emergency room visit with accessible, ongoing outpatient care. AnaOno At the age of 27, Dana Donofree was diagnosed with breast cancer. She took her experience in fashion design and created AnaOno in 2014, a startup that makes bras designed for multiple breast cancer surgery outcomes. The name is a play on her own — it's Dana Donofree, 'DD free.' GoWell When Holly Adams worked as a benefits consultant helping businesses navigate health insurance enrollment, she knew there had to be a better way. For more than a decade, she watched as employers and employees struggled with complicated enrollment processes, long questionnaires and tech that wasn't as accessible as she knew it could be. She took what she'd learned and came up with GoWell Benefits, a platform launched in 2021 that simplifies the enrollment process for employers with an easy and accessible way to insure employees. Atalan When healthcare employees are overworked, they're likely to leave — and that can be a serious problem for the health system. Hiring is expensive. Workplaces with high turnover rates tend to have less employee satisfaction, but when employers ask their employees if they're satisfied, they don't always get straightforward answers that show what the risk of burnout really is. To address these issues, startup founders Tiffany Chan and Sisi Hu, an engineer and a postdoc labor economist who met doing climate change work at Harvard School of Engineering and Applied Sciences, cofounded Atalan, a mission-oriented company with a platform that uses machine learning to help healthcare systems identify workplace risk factors that drive healthcare professionals to leave, in 2022. Yellowdig Yellowdig, a community-focused learning platform, was founded in 2015 by Shaunak Roy. At the time, highly collaborative experiential learning was an impactful trend in education — one that took a hit when the pandemic moved students out of classrooms and into virtual meetings. That shift was an opportunity for Yellowdig. Yellowdig uses technology to foster a more experiential learning environment with engagement and collaboration that enhances what students learn in the classroom. Lithero In life sciences, everything takes longer. Nyron Burke, cofounder and CEO of the Philadelphia-based AI for life sciences company Lithero, learned that through years of working as a consultant with pharmaceutical companies that were always looking for ways to speed up the process of creating marketing materials. What may seem relatively simple, like a pharmaceutical pamphlet for a doctor's office, can take months to finalize due to compliance issues. The final draft, with its medical language and side effects disclosures, has to be just right, requiring multiple reviews by medical lawyers before it goes to print. Burke founded Lithero in 2015, years before AI became a common part of everyday life. He knew that machine learning could make the process considerably faster by screening for compliance issues before a medical lawyer reviews it, cutting down on the number of reviews — and, crucially, time. Tolerance Bio Tolerance Bio focuses on preserving the body's immune system by restoring the function of an organ called the thymus. The organ, long believed to be as useful in adults as the appendix (that is, not at all), may actually be the key to slower aging and prolonged life spans. Now, Tolerance Bio is moving toward the first trials of its proprietary stem cell therapy, focusing first on children born without a thymus. Audigent Audigent's framework for advertisers and publishers allows customers to target their key demographics, as all adtech tools do. The difference with Audigent, now headquartered in NYC, is that it prioritizes the privacy of its potential customers by never using cookies (those small files that websites use to track users' online behavior). Instead, it uses data from partners, like music streamers, media companies and sports sites. Lula Commerce Lula Commerce provides a platform for small retailers to offer online shopping and delivery to their customers using popular apps like DoorDash, UberEats and GrubHub, making it easy for their customers to do business with them online. With Lula, stores that may not have the resources to hire their own team of developers can have a site that integrates multiple ecommerce channels, direct customer service, inventory and returns. In the four years since its founding, the company has rapidly expanded to serve thousands of locations across 44 states.
